September 20, 2010 at 12:36 PM EDT
Novartis's New Lung Disease Drug Trumps GSK's Advair in Study
Shares of Swiss pharmaceutical company Novartis were up about 1.5% in morning trading Monday following its announcement over the weekend that its Onbrez Breezhaler was found to be more effective at treating lung disease than a standard medicine from GlaxoSmithKline. Continue reading Novartis's New Lung Disease Drug Trumps GSK's Advair in Study Novartis's New Lung Disease Drug Trumps GSK's Advair in Study originally appeared on DailyFinance on Mon, 20 Sep 2010 12:36:00. Filed Under: Company News , Health Care , GlaxoSmithKline , Novartis , Stocks in the News Permalink | Tweet this! | Comments
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here